Repros in the News

All Releases

View Summary Repros Therapeutics Inc.(R) Reports Second Quarter 2014 Financial Results

Aug 11, 2014

PDF 25.8 KB Add to Briefcase
View Summary FDA Confirms Sperm and Testosterone Endpoints as Key Parameters for Assessment of Androxal(R) Versus Approved Topical Gel and Placebo

Jul 16, 2014

PDF 68.2 KB Add to Briefcase
View Summary Repros Fully Enrolls Second Previously Announced Head to Head Study of Androxal(R) Versus the Leading Topical Testosterone Gel

May 13, 2014

PDF 67.1 KB Add to Briefcase
View Summary Repros Therapeutics Inc.(R) Reports First Quarter 2014 Financial Results

May 12, 2014

PDF 23.9 KB Add to Briefcase
View Summary FDA Recommends Sperm Endpoints as Key Parameters for Assessment of Androxal(R) Versus Approved Topical Gel

Apr 30, 2014

PDF 68.3 KB Add to Briefcase
View Summary Repros Fully Enrolls First of Two Previously Announced Head to Head Studies of Androxal(R) Versus the Leading Topical Testosterone Gel

Apr 14, 2014

PDF 67.3 KB Add to Briefcase
View Summary Repros Allowed to Conduct Phase 1 and 2 Clinical Studies of Low Dose Oral Proellex(R) in the Treatment of Uterine Fibroids and Endometriosis

Mar 17, 2014

PDF 19.7 KB Add to Briefcase
View Summary Repros Therapeutics Inc.(R) Reports Fourth Quarter and Year End 2013 Financial Results

Mar 13, 2014

PDF 25.5 KB Add to Briefcase
View Summary Repros Reports Findings From the Six Month Study of Androxal(R) in Men With Secondary Hypogonadism

Feb 10, 2014

PDF 26.4 KB Add to Briefcase
View Summary Repros Meets With FDA to Discuss Data Requirements for Androxal(R) in the Treatment of Secondary Hypogonadism

Feb 6, 2014

PDF 24.0 KB Add to Briefcase
View Summary Repros Initiates Two Head to Head Studies of Androxal(R) Versus the Leading Topical Testosterone Gel

Jan 8, 2014

PDF 71.0 KB Add to Briefcase
View Summary Repros Adds Marketing and Commercialization Expertise to Board of Directors

Dec 19, 2013

PDF 19.6 KB Add to Briefcase
View Summary Repros to Present Data on the Benefits of Testosterone Restoration With Androxal(R) Compared to T Replacement With Gels at 9th Men's Health World Congress

Nov 25, 2013

PDF 18.4 KB Add to Briefcase
View Summary FDA Schedules Face to Face Meeting With Repros to Discuss Androxal(R) Efficacy

Nov 25, 2013

PDF 18.2 KB Add to Briefcase
View Summary Repros Therapeutics Inc.(R) Reports Third Quarter 2013 Financial Results

Nov 7, 2013

PDF 25.1 KB Add to Briefcase
View Summary Repros Receives FDA Guidance for Proellex(R) Low Dose Oral Uterine Fibroid Clinical Program

Nov 4, 2013

PDF 19.7 KB Add to Briefcase
View Summary Repros Receives FDA Guidance For Androxal(R) Clinical Program

Oct 22, 2013

PDF 25.0 KB Add to Briefcase
View Summary Repros Announces Three Studies Accepted for Presentation at the Annual Meeting of the Sexual Medicine Society of North America

Oct 7, 2013

PDF 23.7 KB Add to Briefcase
View Summary Repros to Present at Biocentury's NewsMakers in the Biotech Industry Conference

Sep 23, 2013

PDF 21.4 KB Add to Briefcase
View Summary Repros Provides Additional Information Confirming Success for Study ZA-302

Sep 18, 2013

PDF 65.8 KB Add to Briefcase
Showing 61-80 of 197 Page: 1 2 3 4 5 6 7 8 ... 10  Previous 20 | Next 20
Add to Briefcase = add release to Briefcase
2408 Timberloch Place, B-7
The Woodlands, Texas 77380
281-719-3400
281-719-3446 fax